Stem Cell-Derived Sertoli-Like Cells for Immune Privilege
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining Sertoli-like cells are hindered by ethical concerns with embryonic stem cells and low efficiency in isolating adult stem cells, and Sertoli cells themselves do not proliferate after puberty, making it difficult to produce sufficient quantities for therapeutic use.
Innovation Solution
A method involving the differentiation of stem cells into Sertoli-like cells using a medium containing glycogen synthase kinase 3β inhibitor, basic fibroblast growth factor, retinoic acid, fibroblast growth factor 9, prostaglandin D2, follicle-stimulating hormone, and glial cell-derived neurotrophic factor to induce intermediate mesoderm and subsequently Sertoli-like cells, allowing for large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If embryonic stem cells are used for Sertoli cell production, then cell proliferation capability is improved, but ethical problems arise
Solution Approach 1:
The patent uses induced pluripotent stem cells (iPSCs) as an alternative to embryonic stem cells. iPSCs can be generated from adult somatic cells through reprogramming, avoiding ethical issues related to embryo destruction while maintaining the self-renewal and differentiation capabilities needed for Sertoli cell production
Solution Approach 2:
The patent introduces a multi-step differentiation protocol using intermediate mesoderm as a transitional stage. The differentiation pathway proceeds through: iPSCs → intermediate mesoderm → Sertoli-like cells. This intermediary approach enables controlled generation of Sertoli cells with desired functions while avoiding direct use of controversial cell sources
2Object-affected harmful factors
If adult stem cells are isolated from donors, then ethical problems are avoided, but isolation efficiency is low and donor pain occurs
Solution Approach 1:
The patent uses easily accessible somatic cells (such as skin fibroblasts or blood cells) as starting material for iPSC generation. These cells can be obtained through minimally invasive procedures without causing significant pain to donors, and they serve as a renewable source for generating unlimited numbers of Sertoli-like cells
Solution Approach 2:
The patent performs preliminary reprogramming of somatic cells into iPSCs before differentiation. This preliminary action creates a pluripotent state that enables subsequent efficient differentiation into Sertoli-like cells, overcoming the low isolation efficiency limitation of direct adult stem cell harvesting
3Reliability
If Sertoli cells are cultured after puberty, then natural Sertoli cell function is maintained, but cell proliferation stops
Solution Approach 1:
The patent employs dynamic culture conditions that change over time to maintain both proliferation and functionality. The differentiation protocol includes sequential medium changes and factor additions that guide cells through developmental stages, enabling expansion of Sertoli-like cells while preserving their immunosuppressive and protective functions
Solution Approach 2:
The patent modifies cultural parameters such as growth factor concentrations, medium composition, and oxygen levels to induce and maintain Sertoli cell characteristics. By carefully controlling these parameters during differentiation and expansion phases, the patent achieves both high cell numbers and functional maturity
4Productivity
If stem cell differentiation into Sertoli-like cells is achieved, then large-scale production is enabled, but complex differentiation protocols are required
Solution Approach 1:
The patent divides the differentiation process into distinct sequential stages: Stage 1 (iPSC maintenance), Stage 2 (primitive streak formation), Stage 3 (intermediate mesoderm differentiation), and Stage 4 (Sertoli-like cell maturation). Each stage has specific duration, medium composition, and growth factor requirements, making the complex process manageable and scalable
Solution Approach 2:
The patent systematically varies key parameters at each differentiation stage, including GSK3 inhibitor concentration, retinoic acid dosage, FGF9 addition timing, and culture duration. These controlled parameter changes drive cells through the differentiation pathway while maintaining reproducibility for large-scale production
Data Source
AI summary
Provided are stem cells-induced Serotoli-like cells, methods of preparing the same, and uses thereof. Sertoli-like cells according to one embodiment can be differentiated from embryonic stem cells with excellent proliferative capacity, and thus, can be obtained in large quantities. Also, since the Sertoli-like cells secrete immunosuppressive substances and form immune privilege and induce anti-inflammatory functions, they can be used for development of the cell therapeutic agent.